XYYY syndrome: Difference between revisions
CSV import |
CSV import Tags: mobile edit mobile web edit |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{SI}} {{Infobox medical condition | |||
| name = XYYY syndrome | |||
| image = [[File:Peripheral-blood-karyotype-result-belonging-to-the-subject-compatible-with-48-XYYY.png|alt=Karyotype showing 48,XYYY]] | |||
| caption = Karyotype showing 48,XYYY | |||
| synonyms = 48,XYYY syndrome | |||
| pronounce = <!-- Optional phonetic pronunciation --> | |||
| specialty = [[Genetics]] | |||
| symptoms = [[Developmental delay]], [[speech delay]], [[behavioral problems]] | |||
| onset = [[Congenital]] | |||
| duration = Lifelong | |||
| causes = [[Genetic mutation]] | |||
| risks = [[Advanced paternal age]] | |||
| diagnosis = [[Karyotype]] | |||
| differential = [[Klinefelter syndrome]], [[XYY syndrome]] | |||
| treatment = [[Supportive care]], [[speech therapy]], [[occupational therapy]] | |||
| prognosis = Variable | |||
| frequency = Rare | |||
| deaths = Not typically life-threatening | |||
}} | |||
[[File:Picture_of_right_hand.jpg|XYYY syndrome|thumb|left]] | |||
'''Vonoprazan''' is a [[potassium-competitive acid blocker]] (P-CAB) that is used in the treatment of [[acid-related diseases]]. It is a novel type of [[proton pump inhibitor]] (PPI) that has shown to be more effective than traditional PPIs in certain clinical settings. | '''Vonoprazan''' is a [[potassium-competitive acid blocker]] (P-CAB) that is used in the treatment of [[acid-related diseases]]. It is a novel type of [[proton pump inhibitor]] (PPI) that has shown to be more effective than traditional PPIs in certain clinical settings. | ||
== Mechanism of Action == | == Mechanism of Action == | ||
Vonoprazan works by inhibiting the [[hydrogen potassium ATPase]] enzyme in the [[stomach]]. This enzyme is responsible for the final step in the production of gastric acid. By inhibiting this enzyme, vonoprazan reduces the production of stomach acid. | Vonoprazan works by inhibiting the [[hydrogen potassium ATPase]] enzyme in the [[stomach]]. This enzyme is responsible for the final step in the production of gastric acid. By inhibiting this enzyme, vonoprazan reduces the production of stomach acid. | ||
== Clinical Use == | == Clinical Use == | ||
Vonoprazan is used in the treatment of various acid-related diseases, including [[gastroesophageal reflux disease]] (GERD), [[peptic ulcer disease]] (PUD), and [[Helicobacter pylori]] eradication therapy. It has been shown to be more effective than traditional PPIs in the treatment of GERD and PUD, and has also been shown to be more effective in the eradication of H. pylori when used in combination with antibiotics. | Vonoprazan is used in the treatment of various acid-related diseases, including [[gastroesophageal reflux disease]] (GERD), [[peptic ulcer disease]] (PUD), and [[Helicobacter pylori]] eradication therapy. It has been shown to be more effective than traditional PPIs in the treatment of GERD and PUD, and has also been shown to be more effective in the eradication of H. pylori when used in combination with antibiotics. | ||
== Side Effects == | == Side Effects == | ||
The most common side effects of vonoprazan are [[diarrhea]], [[nausea]], and [[abdominal pain]]. Other side effects can include [[headache]], [[dizziness]], and [[rash]]. In rare cases, vonoprazan can cause serious side effects, including [[anaphylaxis]], [[Stevens-Johnson syndrome]], and [[toxic epidermal necrolysis]]. | The most common side effects of vonoprazan are [[diarrhea]], [[nausea]], and [[abdominal pain]]. Other side effects can include [[headache]], [[dizziness]], and [[rash]]. In rare cases, vonoprazan can cause serious side effects, including [[anaphylaxis]], [[Stevens-Johnson syndrome]], and [[toxic epidermal necrolysis]]. | ||
== Contraindications == | == Contraindications == | ||
Vonoprazan is contraindicated in patients with known hypersensitivity to vonoprazan or any of its components. It is also contraindicated in patients with severe liver disease. | Vonoprazan is contraindicated in patients with known hypersensitivity to vonoprazan or any of its components. It is also contraindicated in patients with severe liver disease. | ||
== Drug Interactions == | == Drug Interactions == | ||
Vonoprazan can interact with several other medications, including [[warfarin]], [[digoxin]], and certain [[antifungal drugs]]. It can also interact with certain foods, including grapefruit and grapefruit juice. | Vonoprazan can interact with several other medications, including [[warfarin]], [[digoxin]], and certain [[antifungal drugs]]. It can also interact with certain foods, including grapefruit and grapefruit juice. | ||
== See Also == | == See Also == | ||
* [[Proton pump inhibitor]] | * [[Proton pump inhibitor]] | ||
* [[Gastroesophageal reflux disease]] | * [[Gastroesophageal reflux disease]] | ||
* [[Peptic ulcer disease]] | * [[Peptic ulcer disease]] | ||
* [[Helicobacter pylori]] | * [[Helicobacter pylori]] | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Gastroenterology]] | [[Category:Gastroenterology]] | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
{{stub}} | {{stub}} | ||
Latest revision as of 06:19, 6 April 2025
Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD medical weight loss NYC and sleep center NYC
| XYYY syndrome | |
|---|---|
| |
| Synonyms | 48,XYYY syndrome |
| Pronounce | |
| Specialty | Genetics |
| Symptoms | Developmental delay, speech delay, behavioral problems |
| Complications | N/A |
| Onset | Congenital |
| Duration | Lifelong |
| Types | N/A |
| Causes | Genetic mutation |
| Risks | Advanced paternal age |
| Diagnosis | Karyotype |
| Differential diagnosis | Klinefelter syndrome, XYY syndrome |
| Prevention | N/A |
| Treatment | Supportive care, speech therapy, occupational therapy |
| Medication | N/A |
| Prognosis | Variable |
| Frequency | Rare |
| Deaths | Not typically life-threatening |
Vonoprazan is a potassium-competitive acid blocker (P-CAB) that is used in the treatment of acid-related diseases. It is a novel type of proton pump inhibitor (PPI) that has shown to be more effective than traditional PPIs in certain clinical settings.
Mechanism of Action[edit]
Vonoprazan works by inhibiting the hydrogen potassium ATPase enzyme in the stomach. This enzyme is responsible for the final step in the production of gastric acid. By inhibiting this enzyme, vonoprazan reduces the production of stomach acid.
Clinical Use[edit]
Vonoprazan is used in the treatment of various acid-related diseases, including gastroesophageal reflux disease (GERD), peptic ulcer disease (PUD), and Helicobacter pylori eradication therapy. It has been shown to be more effective than traditional PPIs in the treatment of GERD and PUD, and has also been shown to be more effective in the eradication of H. pylori when used in combination with antibiotics.
Side Effects[edit]
The most common side effects of vonoprazan are diarrhea, nausea, and abdominal pain. Other side effects can include headache, dizziness, and rash. In rare cases, vonoprazan can cause serious side effects, including anaphylaxis, Stevens-Johnson syndrome, and toxic epidermal necrolysis.
Contraindications[edit]
Vonoprazan is contraindicated in patients with known hypersensitivity to vonoprazan or any of its components. It is also contraindicated in patients with severe liver disease.
Drug Interactions[edit]
Vonoprazan can interact with several other medications, including warfarin, digoxin, and certain antifungal drugs. It can also interact with certain foods, including grapefruit and grapefruit juice.
